Which vendors sell Tirzepatide with independent COA testing?

55 vendors in the Merit Verified directory have independent COA evidence on file for Tirzepatide — 449 COAs total. COA coverage and test dates are listed on the Tirzepatide page at https://meritverified.org/peptides/tirzepatide.

How do I verify the quality of Tirzepatide from a vendor?

To verify Tirzepatide quality, look for an independent certificate of analysis (COA) from a third-party lab — not a lab the vendor owns or pays directly. The COA should state the tested compound, lot number, purity percentage (identity and concentration), and the lab's name. Cross-reference the lot number against the vendor's current stock. Merit Verified indexes COAs for Tirzepatide at https://meritverified.org/peptides/tirzepatide so you can compare evidence across vendors before buying.

What is the regulatory status of Tirzepatide?

Tirzepatide is tracked in the Merit Verified registry. Regulatory status for research peptides in the US has been evolving — the FDA has reclassified a number of peptides out of the 503A compounding ingredient list since 2025. Merit Verified does not provide legal or regulatory advice; check official FDA sources or consult a licensed professional for the current status of Tirzepatide in your jurisdiction.

GLP-1 / Metabolic

Tirzepatide

Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)

Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Where to buy · live market data

Who's worth your money for Tirzepatide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

🇺🇸 Polaris Peptides 90

Highest Merit Score (90) of 5 scored sellers

$11.00/mg

$55.00 · 5mg · 99.9% purity

20 COAs

Buy

Best value

🇭🇰 Hkuppeptide 49

Lowest $/mg among scored sellers

$0.50/mg

$10.00 · 20mg · 99.8% purity

1 COA

Buy

Most tested

🇺🇸 Blank Peptides 81

4 independent COAs on file

$2.97/mg

$89.00 · 30mg · 99.6% purity

4 COAs

Buy affiliate

Average price

$6.28/mg

range $0.00–$93.33/mg

Sellers

from $10.00

45-day trend

+21.7%

vs 45-day avg $/mg

69 of 76 sellers have a current price· 64 stale hidden

	Vendor	Price	$/mg	vs avg	Purity	COAs	Merit
🇺🇸	Polaris Peptides ✓ verified at source · just now	$55.00· 5mg	$11.00/mg	+75.3%	99.9%	20	90	Buy
🇺🇸	Blank Peptides ✓ verified at source · just now	$89.00· 30mg	$2.97/mg	-52.7%	99.6%	4	81	Buy affiliate
🇺🇸	Bulk Peptides ✓ verified at source · just now	$380· 20mg	$19.00/mg	+202.8%	—	—	50	Buy
🇭🇰	Hkuppeptide ✓ verified at source · just now	$10.00· 20mg	$0.50/mg	-92%	99.8%	1	49	Buy
🇭🇰	zztai Peptide Ltd ✓ verified at source · just now	$280· 60mg	$4.67/mg	-25.6%	100.0%	1	42	Buy

Top Merit pick

🇺🇸 Polaris Peptides
✓ verified at source · just now
90

$11.00/mg +75.3% vs avg

$55.00

5mg

99.9% purity 20 COAs

Buy
🇺🇸 Blank Peptides
✓ verified at source · just now
81

$2.97/mg -52.7% vs avg

$89.00

30mg

99.6% purity 4 COAs

Buy affiliate
🇺🇸 Bulk Peptides
✓ verified at source · just now
50

$19.00/mg +202.8% vs avg

$380

20mg

no purity

Buy
🇭🇰 Hkuppeptide
✓ verified at source · just now
49

$0.50/mg -92% vs avg

$10.00

20mg

99.8% purity 1 COA

Buy
🇭🇰 zztai Peptide Ltd
✓ verified at source · just now
42

$4.67/mg -25.6% vs avg

$280

60mg

100.0% purity 1 COA

Buy

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tirzepatide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tirzepatide

CAS

2023788-19-2

Molecular formula

C225H348N48O68

Sequence

YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide

Typical dose range

2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)

Half-life

~5 days (~120 hours)

Independent evidence

COAs for Tirzepatide

449 third-party tests across 55 vendors. Each card links to the full report.

All 449 COAs for Tirzepatide →

Measured purity over time

Tirzepatide

Who's worth your money for Tirzepatide

Watch Tirzepatide

About Tirzepatide

COAs for Tirzepatide

23 citations indexed for Tirzepatide

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI

Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol &lt;130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity

Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials